COPD患者血清中nesfatin-1水平及其临床意义

doi:10.3969/j.issn.1671-7171.2018.12.011

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To detect the serum level of nesfatin-1 in patients with stable chronic obstructive pulmonary disease (COPD) and explore its relationship with nutritional indicators and lung function. 【Methods】 A total of 100 patients with stable COPD and 100 healthy volunteers were selected as COPD group and healthy control group, respectively. Serum nesfatin-1 levels were detected by enzyme-linked immunosorbent assay (ELISA), and the nutritional indicators and lung function were detected and compared as well. The nutritional indicators included hemoglobin (Hb) and serum albumin (ALB). The lung function index included percentage of forced expiratory volume in the first second (FEV1),FEV1/FVC. Pearson correlation analysis was used to determine the correlation between serum nesfatin-1 level and nutritional status and lung function in patients with stable COPD. 【Results】 The serum nesfatin-1 level in the COPD group was higher than that in the healthy control group. The Hb, ALB nutritional, FEV1 and FEV1/FVC were significantly lower the healthy group. The differences were statistically significant (P<0.05). The serum nesfatin-1 levels were negatively correlated with Hb, ALB, FEV1, and FEV1/FVC in the COPD group (r=-0.608, -0.522, -0.529, -0.478,P<0.05). 【Conclusion】 Serum nesfatin-1 levels may be a potential biomarker for nutritional assessment and pulmonary function grading in patients with COPD.

Key words： Pulmonary Disease Chronic Obstructive/PP Proteins

Received: 04 September 2018

PACS:

R563.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHU Xiao-hui

Cite this article:

ZHU Xiao-hui. Serum nesfatin-1 Level in patients with COPD and its Clinical Significance[J]. JOURNAL OF CLINICAL RESEARCH, 2018, 35(12): 2323-2325.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2018.12.011 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2018/V35/I12/2323

[1] Vogelmeier CF, Criner GJ, Martínez FJ,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: gold executive summary[J].Arch Bronconeumol,2017 ,53(7):411-412.
[2] Goebel-Stengel M, Stengel A. Role of brain NUCB2/nesfatin-1 in the stress-induced modulation of gastrointestinal functions [J].Curr Neuropharmacol,2016,14(8):882-891.
[3] 沈雅, 韩明锋. 血清白蛋白在慢性阻塞性肺疾病急性加重期患者中的临床意义[J].安徽医药, 2018, 22(6):1126-1129.
[4] 何悠, 白桦, 李荣杰. 阻塞性睡眠呼吸暂停综合征患者血清摄食抑制因子1水平与不同病情程度评价指标之间相关性研究[J].临床肺科杂志, 2017,22(12):2204-2207.
[5] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)(一)[J].中华结核和呼吸杂志, 2014, 36(2):255-264.
[6] 任勇.炎症反应与慢性阻塞性肺疾病并发肺动脉高压的关系分析[J].陕西医学杂志, 2016, 45(5):558-560.
[7] 彭顺刚, 卢建刚, 曾秋蓉,等. 肠内营养支持对老年慢阻肺急性加重期合并呼吸衰竭患者心肺功能及免疫功能的影响[J].临床肺科杂志, 2016,21(2):261-264.
[8] 郑颖文. 慢阻肺急性加重期患者甲状腺激素水平与患者肺功能和营养状况的相关性[J].临床肺科杂志, 2017, 22(6):1056-1059.
[9] 郑国君, 巫小燕, 施正贤,等. 阻塞性睡眠呼吸暂停低通气综合征合并2型糖尿病患者血清Nesfatin-1的变化及意义[J].中国耳鼻咽喉头颈外科, 2017, 24(5):258-261.
[10] 欧阳晓平, 顾扬, 吴峰,等. 阻塞性睡眠呼吸暂停低通气综合征合并2型糖尿病患者血清相关细胞因子变化的临床意义[J].疑难病杂志, 2018,18(6):188-190.
[11] Zhou XP, Sha J, Huang L, et al. Nesfatin-1/NUCB2 in the amygdala influences visceral sensitivity via glucocorticoid and mineralocorticoid receptors in male maternal separation rats [J].Neurogastroenterol Motil,2016, 28(10):1545-1553.
[12] 徐海波, 闫晓光, 钟威. 新诊断2型糖尿病患者血清Nesfatin-1、肿瘤坏死因子-α水平与胰岛素抵抗的相关性研究[J].中国糖尿病杂志, 2017, 25(1):45-48.
[13] Irannejad A, Ghajar A, Afarideh M, et al. Association of peripheral nesfatin-1 with early stage diabetic nephropathy. [J].Pathophysiology,2017, 24(1):17-22.
[14] 刘凌云, 郭进玲, 葛渊. 糖尿病肾病患者血清SFRP5、Klotho表达量与氧化应激、脂肪细胞因子分泌的相关性[J].海南医学院学报, 2017, 23(22):3070-3072.